{ "run": { "id": "cmnr15ml6076pp658r0ndq1s7", "region": "US", "assetId": "cmnr15mjv076dp6589ao0dv0l", "ticker": "ZBH", "snapshotId": "cmnr15mkh076hp658rp2m82en", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:22:12.760Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr15mkh076hp658rp2m82en", "assetId": "cmnr15mjv076dp6589ao0dv0l", "asOf": "2026-04-08T20:00:00.000Z", "snapshot": { "asOf": "2026-04-08T20:00:00.000Z", "quote": { "asOf": "2026-04-08T20:00:00.000Z", "open": 92.84, "price": 93.01, "dayLow": 91.715, "volume": 2128542, "dayHigh": 93.365, "currency": "USD", "prevClose": 91.4, "week52Low": 84.59, "week52High": 108.51 }, "fundamentals": { "pe": 25.2584269662921, "beta": 0.641478262373195, "epsTTM": 3.56, "fcfTTM": 445000000, "growth": { "epsYoy": -0.2, "revenueYoy": 0.07200531346860105 }, "sector": "Orthopedic, Prosthetic & Surgical Appliances & Supplies", "margins": { "net": -0.01977364937006193, "gross": 0.1829881130329561, "operating": -0.01249911025695779 }, "website": "http://zimmerbiomet.com", "industry": null, "pegRatio": -1.26292134831461, "ebitdaTTM": 1883000000, "forwardPe": 10.7175208581645, "marketCap": 18023763265, "totalCash": 591900000, "totalDebt": 7519100000, "debtEquity": 0.592162360112461, "quickRatio": 0.8887641754073615, "revenueTTM": 7024500000, "companyName": "ZIMMER BIOMET HOLDINGS, INC.", "priceToBook": 1.40127344420221, "currentRatio": 1.981615512636916, "dividendYield": 0.0106379632625184, "returnOnAssets": -0.006015148300038542, "returnOnEquity": 0.0555297416067477, "analystOpinions": null, "businessSummary": "Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.", "enterpriseValue": 24731360000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 17000, "sharesOutstanding": 195652004, "enterpriseToEbitda": 13.13402018056293, "analystTargetMedian": null, "enterpriseToRevenue": 3.520728877500178, "operatingCashflowTTM": 1697100000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:22:12.737Z" }, "results": [ { "id": "cmnr15mla076rp658yef9o5yn", "runId": "cmnr15ml6076pp658r0ndq1s7", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"claude-3.7-ai-equity-research\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"ZBH\",\"currency\":\"USD\",\"current_price\":93.01,\"target_price_6m\":99.0,\"target_price_12m\":104.0,\"recommendation\":\"BUY\",\"confidence\":0.58,\"thesis_bullets\":[\"Forward PE of 10.7x suggests depressed TTM earnings may normalize significantly\",\"EV/EBITDA of 13.1x is reasonable for large-cap medtech peer group\",\"Negative GAAP operating margins likely reflect one-time charges, not structural issues\",\"Significant net debt of ~$6.9B constrains balance sheet flexibility near term\",\"Stock trades 14% below 52-week high, offering partial valuation cushion\"],\"key_drivers\":[{\"driver\":\"Normalization of GAAP earnings after one-time charges\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Orthopedic procedure volume recovery post-pandemic backlog\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Revenue growth at 7.2% YoY showing positive momentum\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operating cash flow of $1.7B supports debt reduction\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"High total debt of $7.5B limits strategic flexibility\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"EPS declined 20% YoY indicating near-term headwinds\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Anomalously low gross margin (18.3%) signals potential accounting charges\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Low beta (0.64) provides relative defensiveness\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Margin recovery may take longer than expected if charges recur\",\"Elevated leverage could pressure valuation in rising rate environment\",\"Competitive pressure from Stryker and J&J in core orthopedic segments\",\"Potential regulatory or reimbursement headwinds in key markets\",\"Macroeconomic slowdown could defer elective surgical procedures\"],\"assumptions\":{\"revenue_cagr_3y\":0.045,\"ebit_margin_target\":0.26,\"wacc\":0.085,\"terminal_multiple\":13.0},\"scenarios\":{\"bear\":{\"target_price\":82.0,\"prob\":0.20,\"notes\":\"Persistent margin pressure and slower procedure volumes compress multiples.\"},\"base\":{\"target_price\":104.0,\"prob\":0.55,\"notes\":\"Earnings normalize toward forward estimates with steady mid-single-digit revenue growth.\"},\"bull\":{\"target_price\":120.0,\"prob\":0.25,\"notes\":\"Accelerating volumes and margin expansion drive multiple re-rating toward medtech peers.\"}},\"method_notes\":\"Blended EV/EBITDA and normalized earnings approach. Snapshot shows negative GAAP margins but healthy EBITDA ($1.88B) and OCF ($1.7B), suggesting large non-cash/one-time charges depressing reported earnings. Forward PE of 10.7x implies ~$8.68 adj EPS; applied 12-13x multiple for base target. Checked EV/EBITDA vs medtech comps (12-15x range). Net debt ~$6.9B factored in. Moderate confidence due to margin opacity and debt load. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "claude-3.7-ai-equity-research", "risks": [ "Margin recovery may take longer than expected if charges recur", "Elevated leverage could pressure valuation in rising rate environment", "Competitive pressure from Stryker and J&J in core orthopedic segments", "Potential regulatory or reimbursement headwinds in key markets", "Macroeconomic slowdown could defer elective surgical procedures" ], "ticker": "ZBH", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Earnings normalize toward forward estimates with steady mid-single-digit revenue growth.", "target_price": 104 }, "bear": { "prob": 0.2, "notes": "Persistent margin pressure and slower procedure volumes compress multiples.", "target_price": 82 }, "bull": { "prob": 0.25, "notes": "Accelerating volumes and margin expansion drive multiple re-rating toward medtech peers.", "target_price": 120 } }, "confidence": 0.58, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.045, "terminal_multiple": 13, "ebit_margin_target": 0.26 }, "key_drivers": [ { "driver": "Normalization of GAAP earnings after one-time charges", "impact": "HIGH", "direction": "POS" }, { "driver": "Orthopedic procedure volume recovery post-pandemic backlog", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue growth at 7.2% YoY showing positive momentum", "impact": "MED", "direction": "POS" }, { "driver": "Operating cash flow of $1.7B supports debt reduction", "impact": "MED", "direction": "POS" }, { "driver": "High total debt of $7.5B limits strategic flexibility", "impact": "HIGH", "direction": "NEG" }, { "driver": "EPS declined 20% YoY indicating near-term headwinds", "impact": "HIGH", "direction": "NEG" }, { "driver": "Anomalously low gross margin (18.3%) signals potential accounting charges", "impact": "MED", "direction": "NEG" }, { "driver": "Low beta (0.64) provides relative defensiveness", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended EV/EBITDA and normalized earnings approach. Snapshot shows negative GAAP margins but healthy EBITDA ($1.88B) and OCF ($1.7B), suggesting large non-cash/one-time charges depressing reported earnings. Forward PE of 10.7x implies ~$8.68 adj EPS; applied 12-13x multiple for base target. Checked EV/EBITDA vs medtech comps (12-15x range). Net debt ~$6.9B factored in. Moderate confidence due to margin opacity and debt load. Not investment advice.", "current_price": 93.01, "recommendation": "BUY", "thesis_bullets": [ "Forward PE of 10.7x suggests depressed TTM earnings may normalize significantly", "EV/EBITDA of 13.1x is reasonable for large-cap medtech peer group", "Negative GAAP operating margins likely reflect one-time charges, not structural issues", "Significant net debt of ~$6.9B constrains balance sheet flexibility near term", "Stock trades 14% below 52-week high, offering partial valuation cushion" ], "target_price_6m": 99, "target_price_12m": 104 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 111548, "createdAt": "2026-04-09T05:22:12.760Z", "usage": { "inputTokens": 3589, "outputTokens": 2132, "costUsd": 0.071245 } }, { "id": "cmnr15mla076up658r7w3b2dk", "runId": "cmnr15ml6076pp658r0ndq1s7", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Research\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"ZBH\",\n \"currency\": \"USD\",\n \"current_price\": 93.01,\n \"target_price_6m\": 96.0,\n \"target_price_12m\": 100.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\"EPS recovery from cost efficiency initiatives.\", \"Revenue growth driven by aging demographics.\", \"Margin improvement targets support profitability.\", \"Strong cash flow aids debt reduction.\", \"Valuation attractive on forward earnings.\"],\n \"key_drivers\": [\n { \"driver\": \"New product adoption\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Cost reduction programs\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt management\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approvals\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Competition intensity\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Economic conditions\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency fluctuations\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\"Execution risk on margin targets.\", \"Delays in product approvals.\", \"Increased competition from peers.\", \"Adverse healthcare policy changes.\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.055,\n \"ebit_margin_target\": 0.08,\n \"wacc\": 0.08,\n \"terminal_multiple\": 12.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 80.0, \"prob\": 0.2, \"notes\": \"Slower growth and margin pressures persist.\" },\n \"base\": { \"target_price\": 100.0, \"prob\": 0.6, \"notes\": \"Moderate recovery as per guidance.\" },\n \"bull\": { \"target_price\": 120.0, \"prob\": 0.2, \"notes\": \"Strong execution and market share gains.\" }\n },\n \"method_notes\": \"DCF with assumed growth and margin improvement. BUY based on 8% upside to 12M target. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "AI_Equity_Research", "risks": [ "Execution risk on margin targets.", "Delays in product approvals.", "Increased competition from peers.", "Adverse healthcare policy changes." ], "ticker": "ZBH", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Moderate recovery as per guidance.", "target_price": 100 }, "bear": { "prob": 0.2, "notes": "Slower growth and margin pressures persist.", "target_price": 80 }, "bull": { "prob": 0.2, "notes": "Strong execution and market share gains.", "target_price": 120 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.055, "terminal_multiple": 12, "ebit_margin_target": 0.08 }, "key_drivers": [ { "driver": "New product adoption", "impact": "HIGH", "direction": "POS" }, { "driver": "Cost reduction programs", "impact": "MED", "direction": "POS" }, { "driver": "Debt management", "impact": "LOW", "direction": "POS" }, { "driver": "Regulatory approvals", "impact": "MED", "direction": "NEG" }, { "driver": "Competition intensity", "impact": "HIGH", "direction": "NEG" }, { "driver": "Economic conditions", "impact": "MED", "direction": "NEG" }, { "driver": "Currency fluctuations", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF with assumed growth and margin improvement. BUY based on 8% upside to 12M target. not investment advice.", "current_price": 93.01, "recommendation": "BUY", "thesis_bullets": [ "EPS recovery from cost efficiency initiatives.", "Revenue growth driven by aging demographics.", "Margin improvement targets support profitability.", "Strong cash flow aids debt reduction.", "Valuation attractive on forward earnings." ], "target_price_6m": 96, "target_price_12m": 100 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 372, "createdAt": "2026-04-09T05:22:12.760Z", "usage": { "inputTokens": 2097, "outputTokens": 4354, "costUsd": 0.002416 } }, { "id": "cmnr15mla076sp658w8ve7pud", "runId": "cmnr15ml6076pp658r0ndq1s7", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"ZBH_Equity_Model_v1\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"ZBH\",\n \"currency\": \"USD\",\n \"current_price\": 93.01,\n \"target_price_6m\": 100.00,\n \"target_price_12m\": 108.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.70,\n \"thesis_bullets\": [\n \"Forward P/E of 10.7x presents an attractive entry point for a medtech market leader.\",\n \"ROSA robotics platform adoption is accelerating, defending market share in knee and hip implants.\",\n \"Shift of orthopedic procedures to ASCs creates new revenue opportunities despite pricing headwinds.\",\n \"Near-term margin pressures exist, but operational restructuring should drive profitability improvements.\",\n \"Demographic tailwinds from an aging population ensure durable long-term demand for joint replacements.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"ROSA Robotics Adoption\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Elective Surgery Volume Normalization\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital CapEx Constraints\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Ambulatory Surgery Center (ASC) Penetration\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Supply Chain and Inflation Pressures\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"GLP-1 Impact on Obesity-Related Joint Wear\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Intense competition from Stryker and J&J in the robotics and implant space.\",\n \"Pricing pressure from hospital consolidation and government payers.\",\n \"Macroeconomic pressures limiting elective procedures and hospital capital budgets.\",\n \"Execution risks related to ongoing margin recovery and restructuring initiatives.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.045,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.085,\n \"terminal_multiple\": 12.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 75.00,\n \"prob\": 0.25,\n \"notes\": \"Hospital CapEx freezes and intense competition from Stryker erode market share, compressing multiples.\"\n },\n \"base\": {\n \"target_price\": 108.00,\n \"prob\": 0.60,\n \"notes\": \"Steady mid-single-digit revenue growth and margin normalization drive earnings recovery.\"\n },\n \"bull\": {\n \"target_price\": 125.00,\n \"prob\": 0.15,\n \"notes\": \"Rapid ROSA adoption and strong ASC penetration lead to multiple expansion toward historical medtech averages.\"\n }\n },\n \"method_notes\": \"Valuation based on 13x NTM EPS and 12x EV/EBITDA, reflecting a discount to historical medtech averages due to recent margin compression. Target implies ~16% upside, supporting a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ZBH_Equity_Model_v1", "risks": [ "Intense competition from Stryker and J&J in the robotics and implant space.", "Pricing pressure from hospital consolidation and government payers.", "Macroeconomic pressures limiting elective procedures and hospital capital budgets.", "Execution risks related to ongoing margin recovery and restructuring initiatives." ], "ticker": "ZBH", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady mid-single-digit revenue growth and margin normalization drive earnings recovery.", "target_price": 108 }, "bear": { "prob": 0.25, "notes": "Hospital CapEx freezes and intense competition from Stryker erode market share, compressing multiples.", "target_price": 75 }, "bull": { "prob": 0.15, "notes": "Rapid ROSA adoption and strong ASC penetration lead to multiple expansion toward historical medtech averages.", "target_price": 125 } }, "confidence": 0.7, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.045, "terminal_multiple": 12, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "ROSA Robotics Adoption", "impact": "HIGH", "direction": "POS" }, { "driver": "Elective Surgery Volume Normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Hospital CapEx Constraints", "impact": "MED", "direction": "NEG" }, { "driver": "Ambulatory Surgery Center (ASC) Penetration", "impact": "MED", "direction": "POS" }, { "driver": "Supply Chain and Inflation Pressures", "impact": "MED", "direction": "NEG" }, { "driver": "GLP-1 Impact on Obesity-Related Joint Wear", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on 13x NTM EPS and 12x EV/EBITDA, reflecting a discount to historical medtech averages due to recent margin compression. Target implies ~16% upside, supporting a BUY rating. Not investment advice.", "current_price": 93.01, "recommendation": "BUY", "thesis_bullets": [ "Forward P/E of 10.7x presents an attractive entry point for a medtech market leader.", "ROSA robotics platform adoption is accelerating, defending market share in knee and hip implants.", "Shift of orthopedic procedures to ASCs creates new revenue opportunities despite pricing headwinds.", "Near-term margin pressures exist, but operational restructuring should drive profitability improvements.", "Demographic tailwinds from an aging population ensure durable long-term demand for joint replacements." ], "target_price_6m": 100, "target_price_12m": 108 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 26818, "createdAt": "2026-04-09T05:22:12.760Z", "usage": { "inputTokens": 2448, "outputTokens": 862, "costUsd": 0.01524 } }, { "id": "cmnr15mla076qp658s2rl9kwr", "runId": "cmnr15ml6076pp658r0ndq1s7", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI Equity Analyst v2\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"ZBH\",\"currency\":\"USD\",\"current_price\":93.01,\"target_price_6m\":98.5,\"target_price_12m\":104,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Core orthopedics demand remains resilient as aging demographics support procedures.\",\"Forward valuation looks undemanding versus medtech peers and normalized earnings power.\",\"Robotics and implant innovation can support mix and surgeon retention.\",\"Cost actions and easier comparisons should lift margins and free cash flow.\",\"Leverage, pricing pressure, and uneven GAAP profitability cap upside.\"],\"key_drivers\":[{\"driver\":\"Knee/hip procedure volumes\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"ROSA robotics adoption\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Product mix innovation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Cost discipline execution\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Free cash flow conversion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"China pricing pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Restructuring/legal charges\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Deleveraging pace\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Procedure demand softens from macro or staffing pressures.\",\"Hospital pricing pressure compresses implant margins.\",\"Execution missteps delay margin recovery and cash conversion.\",\"High debt limits flexibility if growth disappoints.\"],\"assumptions\":{\"revenue_cagr_3y\":4.5,\"ebit_margin_target\":20.5,\"wacc\":8.4,\"terminal_multiple\":13},\"scenarios\":{\"bear\":{\"target_price\":84,\"prob\":0.25,\"notes\":\"Volumes slow and pricing pressure offsets cost actions.\"},\"base\":{\"target_price\":104,\"prob\":0.5,\"notes\":\"Low-single-digit growth and margin normalization support rerating.\"},\"bull\":{\"target_price\":118,\"prob\":0.25,\"notes\":\"Robotics traction and stronger margins drive faster deleveraging.\"}},\"method_notes\":\"12M target blends normalized EV/EBITDA and FCF-yield using snapshot price, debt, and cash; external context only informed business mix and execution trends. No sell-side targets used. Snapshot GAAP margins appear charge-distorted versus EBITDA, so profitability is normalized in assumptions. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "OpenAI Equity Analyst v2", "risks": [ "Procedure demand softens from macro or staffing pressures.", "Hospital pricing pressure compresses implant margins.", "Execution missteps delay margin recovery and cash conversion.", "High debt limits flexibility if growth disappoints." ], "ticker": "ZBH", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Low-single-digit growth and margin normalization support rerating.", "target_price": 104 }, "bear": { "prob": 0.25, "notes": "Volumes slow and pricing pressure offsets cost actions.", "target_price": 84 }, "bull": { "prob": 0.25, "notes": "Robotics traction and stronger margins drive faster deleveraging.", "target_price": 118 } }, "confidence": 0.62, "assumptions": { "wacc": 8.4, "revenue_cagr_3y": 4.5, "terminal_multiple": 13, "ebit_margin_target": 20.5 }, "key_drivers": [ { "driver": "Knee/hip procedure volumes", "impact": "HIGH", "direction": "POS" }, { "driver": "ROSA robotics adoption", "impact": "MED", "direction": "POS" }, { "driver": "Product mix innovation", "impact": "MED", "direction": "POS" }, { "driver": "Cost discipline execution", "impact": "HIGH", "direction": "POS" }, { "driver": "Free cash flow conversion", "impact": "MED", "direction": "POS" }, { "driver": "China pricing pressure", "impact": "MED", "direction": "NEG" }, { "driver": "Restructuring/legal charges", "impact": "MED", "direction": "NEG" }, { "driver": "Deleveraging pace", "impact": "LOW", "direction": "POS" } ], "method_notes": "12M target blends normalized EV/EBITDA and FCF-yield using snapshot price, debt, and cash; external context only informed business mix and execution trends. No sell-side targets used. Snapshot GAAP margins appear charge-distorted versus EBITDA, so profitability is normalized in assumptions. not investment advice", "current_price": 93.01, "recommendation": "BUY", "thesis_bullets": [ "Core orthopedics demand remains resilient as aging demographics support procedures.", "Forward valuation looks undemanding versus medtech peers and normalized earnings power.", "Robotics and implant innovation can support mix and surgeon retention.", "Cost actions and easier comparisons should lift margins and free cash flow.", "Leverage, pricing pressure, and uneven GAAP profitability cap upside." ], "target_price_6m": 98.5, "target_price_12m": 104 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_08f2ccedb2b1b25a0069d75f1019e88193a47e5be8dc66d659", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 49612, "createdAt": "2026-04-09T05:22:12.760Z", "usage": { "inputTokens": 2364, "outputTokens": 2800, "costUsd": 0.043337 } }, { "id": "cmnr15mla076tp658c7cjoiec", "runId": "cmnr15ml6076pp658r0ndq1s7", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"ZBH DCF Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:00.000Z\",\n \"ticker\": \"ZBH\",\n \"currency\": \"USD\",\n \"current_price\": 93.01,\n \"target_price_6m\": 100,\n \"target_price_12m\": 107,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Aging demographics drive orthopedic volume\",\n \"Robotic pipeline to gain market share\",\n \"FCF supports dividend and debt repair\",\n \"Forward P/E signals margin expansion\",\n \"Competition and reimbursement limit upside\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Aging population demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Product innovation pipeline\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Cost optimization programs\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Industry competition\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Hospital budget constraints\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory approvals\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"High debt levels\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A integration success\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Hospital capital spending cuts\",\n \"Supply chain disruptions\",\n \"Foreign exchange volatility\",\n \"Increased competition in spine\",\n \"Regulatory and reimbursement changes\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.2,\n \"wacc\": 0.085,\n \"terminal_multiple\": 15\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 78,\n \"prob\": 0.3,\n \"notes\": \"Persistent margins issues and recession hit.\"\n },\n \"base\": {\n \"target_price\": 107,\n \"prob\": 0.5,\n \"notes\": \"Moderate growth with successful cost cuts.\"\n },\n \"bull\": {\n \"target_price\": 130,\n \"prob\": 0.2,\n \"notes\": \"Strong tech adoption and earnings beats.\"\n }\n },\n \"method_notes\": \"DCF using 6% rev CAGR, 20% EBIT target, 8.5% WACC, 15x terminal. 15% 12M upside supports BUY on recovery vs mixed margins. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:00.000Z", "model": "ZBH DCF Valuation Model", "risks": [ "Hospital capital spending cuts", "Supply chain disruptions", "Foreign exchange volatility", "Increased competition in spine", "Regulatory and reimbursement changes" ], "ticker": "ZBH", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth with successful cost cuts.", "target_price": 107 }, "bear": { "prob": 0.3, "notes": "Persistent margins issues and recession hit.", "target_price": 78 }, "bull": { "prob": 0.2, "notes": "Strong tech adoption and earnings beats.", "target_price": 130 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 15, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Aging population demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Product innovation pipeline", "impact": "HIGH", "direction": "POS" }, { "driver": "Cost optimization programs", "impact": "MED", "direction": "POS" }, { "driver": "Industry competition", "impact": "HIGH", "direction": "NEG" }, { "driver": "Hospital budget constraints", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory approvals", "impact": "MED", "direction": "NEG" }, { "driver": "High debt levels", "impact": "MED", "direction": "NEG" }, { "driver": "M&A integration success", "impact": "LOW", "direction": "POS" } ], "method_notes": "DCF using 6% rev CAGR, 20% EBIT target, 8.5% WACC, 15x terminal. 15% 12M upside supports BUY on recovery vs mixed margins. Not investment advice.", "current_price": 93.01, "recommendation": "BUY", "thesis_bullets": [ "Aging demographics drive orthopedic volume", "Robotic pipeline to gain market share", "FCF supports dividend and debt repair", "Forward P/E signals margin expansion", "Competition and reimbursement limit upside" ], "target_price_6m": 100, "target_price_12m": 107 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "0b763d91-0f9f-9c35-b8bf-456eca96f2c2", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 19274, "createdAt": "2026-04-09T05:22:12.760Z", "usage": { "inputTokens": 2706, "outputTokens": 3118, "costUsd": 0.054888 } } ] } }